I challenge you to find a Biotech on the ASX which represents better value than CUV.
ROTFL. Most Companies are listed on the ASX because they can't find anyone to buy their worthless technology. The only thing CUV has actually achieved is getting orphan drug status for a 40 year old drug after 15 years of effort. If you knew anything about the drug approval process you would know orphan drug status isn't hard to obtain.
It seems that most HC 'investors'' actually have absolutely zero formal training or expertise in any of the the technologies they invest in. Many don't even have HSC yet they are self-proclaimed ''experts"' in extremely complex businesses and technologies that probably require a PhD and decades of experience to fully comprehend. They are typically paranoid and accuse of everyone who doesn't have the same starry eyed enthusiasm of being a shorter.
Ann: Media release - First stroke patient with afamelanotide, page-21
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.81 |
Change
0.230(1.58%) |
Mkt cap ! $741.1M | |||
| Open | High | Low | Value | Volume |
| $14.61 | $14.99 | $14.40 | $828.3K | 56.64K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 1099 | $14.79 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.81 | 358 | 15 |
View Market Depth
| Last trade - 14.05pm 10/07/2024 (20 minute delay) ? |
| CUV (ASX) Chart |